Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Short-Term Cardiovascular Effects of E-Cigarettes: Influence of E-Liquid pH

A legfontosabb adatok

Ki végzi
University of California, San Francisco
Hol
San Francisco (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Befejeződött
Résztvevők
14 fő vett részt
Kezdés
2021. jan. 4.
Befejezés
2024. júl. 31.
A vizsgálat típusa
Beavatkozással járó, 3 csoport
A vizsgált kezelések
  • Electronic Cigarette
A regiszteradat frissítve
2025. július 15.

Ki vehet részt

Életkor
21 év – 70 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 53 feltétel megnézéseKevesebb

Ki vehet részt

  • Heart rate < 105 beats per minute (BPM)*
  • Systolic Blood pressure <160 and > 90*
  • Diastolic Blood Pressure <100 and > 50*
  • Body Mass Index (BMI) < 38.0 (at investigator's discretion for higher BMI if no other concurrent health issues); *considered out of range if both machine and manual readings are above/below these thresholds
  • Use e-cigarettes on at least 15 days in the past 30 for at least 3 months
  • Smoke 10 or fewer cigarettes/tobacco products per day in the last 30 days
  • Willing to use mod e-cigarette
  • Willing to abstain from tobacco product use for night before study
  • Age: > 21 years old and < 70 years old
  • Using e-liquid > 0mg/ml nicotine
  • Saliva cotinine of ≥ 30 ng/ml or NicAlert=6 (in cases where lab turn around time will delay study procedure)

Ki nem vehet részt

  • High Blood Pressure (taking sympatholytic medications such as alpha and beta blockers)
  • Drug/Alcohol Dependence
  • Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program
  • Positive toxicology test at the screening visit (THC \& prescribed medications okay)
  • Opioid replacement therapy (including methadone, buprenorphine, or other)
  • Medications
  • Use of medications that are inducers of nicotine metabolizing enzyme CYP2A4 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs)
  • Concurrent use of nicotine-containing medications
  • Concurrent participation in another clinical trial
  • Seizures
  • Cancer
  • Hepatitis B or C or Liver Disease
  • Heart disease
  • Kidney disease or urinary retention
  • Diabetes
  • History of stroke
  • An ulcer in the past year
  • Thyroid disease (okay if controlled with medication)
  • Active use of an inhaler for asthma or Chronic Obstructive Pulmonary Disease (COPD)
  • Psychiatric conditions
  • Current or past schizophrenia, and/or current or past bipolar disorder
  • Major personality disorder
  • Participants with current or past minor or moderate depression and/or anxiety disorders will be reviewed by the study physician and considered for inclusion
  • History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per study physician's approval
  • Psychiatric medications
  • Current regular use of any psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitor (SSRI) and serotonin-norepinephrine reuptake Inhibitor (SNRIs) and current evaluation by the study physician that the participant is otherwise healthy, stable, and able to participate
  • Any stimulant medications (example: Adderall) generally given for Attention deficit hyperactivity disorder (ADHD) treatment
  • Use of sympatholytic medications that affect cardiovascular conditions including hypertension, (Example: beta and alpha-blockers)
  • Other/Misc. Chronic Health Conditions
  • Other "life threatening illnesses" as per study physician's discretion
  • Oral Thrush
  • Glaucoma
  • Major depression, current or within the past year
  • Recent onset or change in cough, fever and/or abdominal symptoms (vomiting or pain) in the past two weeks. (If yes, participant can re-screen when symptoms resolve)
  • Positive urine cannabis is not exclusionary but participant must report use of cannabis and agree to abstain from cannabis use for the duration of the study
  • Fainting (within the last 30 days)
  • Pregnancy
  • Pregnancy (self-reported and urine pregnancy test)
  • Breastfeeding (determined by self-report)
  • Inability to communicate in English
  • Planning to quit vaping within the next 60 days
  • Uncomfortable with getting blood drawn

Helyszínek itt: Egyesült Államok

  • University of California San FranciscoSan Francisco, Egyesült Államok
  • Zuckerberg San Francisco General HospitalSan Francisco, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study will examine the short-term cardiovascular (CV) effects of e-liquid pH in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=21). The specific aim is to determine the impact of e-cigarette pH levels on nicotine pharmacology, systemic exposure to toxic volatile organic compounds (VOCs), and short-term cardiovascular effects.

A vizsgálat 3 csoportja

  • E-liquid pH 5, 7, or 9Egyéb csoport

    Using an electronic cigarette, the participant will complete a standardized vaping session using 1 of 3 assigned e-liquid pH.

    Kezelés: Electronic Cigarette

  • 1 of the other 2 remaining e-liquid pHEgyéb csoport

    Using an electronic cigarette, the participant will complete a standardized vaping session using 1 of the other 2 assigned e-liquid pH.

    Kezelés: Electronic Cigarette

  • Remaining e-liquid pHEgyéb csoport

    Using an electronic cigarette, the participant will complete a standardized vaping session using the remaining assigned e-liquid pH.

    Kezelés: Electronic Cigarette

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2025. július 15.